Bayer has over 30 years of research and development in hemophilia, exemplified best by our portfolio of recombinant FVIII therapies, which include Kogenate FS/Bayer, Kovaltry, and Jivi.
Besides improving FVIII replacement therapy, Bayer is also pursuing alternative treatment approaches in hemophilia, including gene therapy.